

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373

Provisional Stakeholder List


Consultees	Commentators (no right to submit or
	appeal)
Company	General
Eli Lilly and Company (imlunestrant)	All Wales Therapeutics and Toxicology Centre
 Patient/carer groups Black Health Agency for Equality Breast Cancer Now Breast Cancer UK Cancer Black Care Cancer Equality Helen Rollason Cancer Charity Independent Cancer Patients Voice Inflammatory Breast Cancer (IBC) Network UK Lobular Breast Cancer UK Macmillan Cancer Support Maggie's Centres Make 2nds Count Marie Curie MET UP UK 	 Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services
Prevent Breast CancerSouth Asian Health Foundation	Committee
Specialised Healthcare AllianceTenovus Cancer Care	 Possible comparator companies AAH Pharmaceuticals (everolimus, exemestane)
 Healthcare professional groups Association of Breast Surgery Association of Cancer Physicians British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Interventional Radiology Cancer Research UK Royal College of General Practitioners 	 Accord UK (capecitabine, docetaxel, everolimus, exemestane, gemcitabine, paclitaxel) Alliance Healthcare (Distribution) (exemestane) Amarox (capecitabine) AstraZeneca (capivasertib, fulvestrant, olaparib) Bristol Myers Squibb Pharmaceuticals (paclitaxel) Consilient Health (docetaxel, exemestane, gemcitabine, vinorelbine)

Provisional stakeholder list for the evaluation of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373 Issue date: September 2025



Consultees	Commentators (no right to submit or appeal)
 Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Breast Cancer Group UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Dr Reddy's Laboratories (capecitabine, everolimus, fulvestrant) Eli Lilly (abemaciclib) Fresenius Kabi (gemcitabine, paclitaxel) Glenmark Pharmaceuticals (capecitabine, exemestane) Kent Pharma UK (exemestane, fulvestrant) Martindale Pharmaceuticals (everolimus) Medac (vinorelbine) Medihealth (Northern) (exemestane) Morningside Healthcare (capecitabine, exemestane) Novartis (alpelisib, everolimus, ribociclib) Pfizer (docetaxel, exemestane, gemcitabine, palbociclib, paclitaxel, talazoparib) Phoenix Healthcare Distribution (exemestane) Pierre Fabre (vinorelbine) Rivopharm (exemestane) Sandoz (everolimus, fulvestrant) Seacross Pharmaceuticals (docetaxel, paclitaxel) Sigma Pharmaceutical Industries Europe (fulvestrant, gemcitabine) Synchrony Pharma (gemcitabine) Teva UK (everolimus, fulvestrant) Thornton & Ross (fulvestrant) Viatris UK Healthcare (exemestane) Waverley Pharma Europe (capecitabine) Zentiva (exemestane, fulvestrant) Relevant research groups Against Breast Cancer Breast Cancer Hope Cochrane UK Genomics England

Provisional stakeholder list for the evaluation of imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy ID6373 Issue date: September 2025



Consultees	Commentators (no right to submit or appeal)
	 Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Pro-Cancer Research Fund
	 Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.